Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israël, Tel Aviv
Ronit El Hasid
38 années d'expérience
La clinique est certifiée :
| Israël | Turquie | Espagne | |
| Test sanguin avec marqueur tumoral | de $100 | de $100 | de $50 |
Bookimed ne facture pas de frais supplémentaires pour les prix des Test sanguin avec marqueur tumoral. Les tarifs sont issus des listes de prix officielles des cliniques. Vous payez directement à la clinique lors de votre arrivée pour votre Test sanguin avec marqueur tumoral.
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans Test sanguin avec marqueur tumoral et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de Test sanguin avec marqueur tumoral.
Le médecin est le chef du département d'oncohématologie et d'oncologie pédiatrique à l'hôpital pour enfants Dana Dwek. Spécialisé dans les transplantations de moelle osseuse et de sang de cordon ombilical pour les enfants, le médecin a réalisé plus de 300 transplantations. Avec une forte présence académique, le médecin a publié 50 articles et présenté 40 rapports lors de diverses conférences médicales. Le médecin est membre de l'Association américaine d'hématologie et de la Société israélienne d'hémato-oncologie pédiatrique, et a exercé à l'hôpital City of Hope à Los Angeles et dans divers centres médicaux en Israël.<\/p>
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Professor Dov Zippel is a general surgeon and surgical oncologist. He specializes in breast disease and melanoma. He leads the Meirav Breast Center at Sheba Medical Center. He also serves at the Ella Lemelbaum Institute for Immuno-Oncology. In 2025, Forbes Israel named him to its Best Doctors list.
Expertise: advanced care for benign and malignant breast tumors. Minimally invasive and breast-conserving surgery. Surgical treatment of melanoma and other skin cancers.
Accreditations: MD, Tel Aviv University. Residency in general surgery, Sheba Medical Center. Fellowship in surgical oncology, University of Calgary. Board-certified in general surgery and surgical oncology. Research includes intact breast lesion excision and perioperative BRAF inhibitors for stage III melanoma.